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ABSTRACT 
    Background: Ankle injury is common for soccer players. The number of peripheral blood stem cells (PBSC), is a key parameter in 
the extent of recovery. In animal studies, StemEnhance® shows accelerated muscle repair after induced muscle injury, and shown to 
trigger a significant increase in the number of PBSC.  Determine whether SE2® could enhance the effectiveness of conventional 
treatment for ankle injuries. Methods: Twelve male soccer players were randomly assigned, to either experimental (SE2®) or control 
group. Both groups received conventional treatment. The experimental group received 12 capsules of SE2® daily for a month. The 
team’s doctor evaluated patients with soft tissue sonograms at days 1, 7, 14 and 21. The Karlsson Peterson Scoring for Ankle function 
was taken every other day. The acute ankle injury was similar in both groups. The participants were matched. The SE2® group 
experienced a significantly reduction in pain, range of motion and joint stability compared with control group. Recovery time was on 
average 17 days for the SE2® group versus 21 days for the control group. The use of the stem cell mobilizer SE2® in conjunction with 
conventional treatment reduced the recovery time from acute ankle injuries in male football players. 
            Keyword: SE2, Stem cells mobilizer, ankle injury, sport injury, stem cell, ligaments 
 
INTRODUCTION  
Soccer is one of the most popular sports worldwide with about 265 
million players, both professionals and amateurs (Herrero et al., 
12013). This popularity has massive financial implications 
especially when considering professional soccer. Extensive 
research has been done regarding types of injuries, with emphasis 
on professional players, since they have a greater exposure than 
soccer players at the recreational level. One of the most significant 
findings from the epidemiological studies of Woods et al. (2002, 
2003) was the disproportionately high number of training injuries 
during preseason, and match injuries during the early stages of the 
season.  Several reasons for this increased incidence have been 
suggested, including hard playing surface (Dragoo and Braun, 
2010), high training intensity (Gabbett and Ullah, 2012), sudden 
change in training intensity from closed season to preseason, and 
short preseason preparation (Pontillo et al., 2014).  
The most common injuries are muscle and ligaments sprains, with 
muscle sprains being the first and most common of both injuries 
observed during preseason (Woods et al., 2002).  It is crucial to 
the practice of sport medicine to find new ways of reducing the 
healing time and improving total recovery for these type of 
injuries and athletes.   
Injuries to the skin, bones and muscles were shown to trigger 
mobilization of bone marrow-derived stem cells (BMSC) and 
their migration into the injured tissue where they participate to the 
process of tissue repair. (Matsumoto et al., 2008; Lee et al., 2008; 
Mansilla et al., 2006; Mace et al., 2009; Stout et al., 2007)   It was 
documented that the speed and extent of tissue repair depends in 
part on the number of peripheral blood stem cells (PBSC) 
available to migrate into an injured tissue (Wu et al, 2007; 
Velasquez et al., 2007; Tomoda and Aoki, 2003).  The stem cell 
mobilizer StemEnhance®10 has been shown in an animal study to 
accelerate muscle repair after induced muscle injury (Drapeau et 
al., 2010).  StemEnhance® is a natural product containing an 
L-selectin blocker that works by interfering with the 
SDF-1/CXCR4 axis in the bone marrow, triggering stem cell 
mobilization (Jensen et al., 2007).  Both StemEnhance® and its 
advanced formula SE2® have been shown to trigger a mild 
increase in the number of PBSC unfolding a great potential at the 
clinical level. This study was aimed at investigating the clinical 
potential of Endogenous Bone Marrow Stem Cell Mobilization 
(ESCM) using the stem cell mobilizer SE2®, when used along 
with conventional treatment for sport ankle injuries, in order to 
decrease recovery time and reduce the critical off match time for 
professional soccer players.   
 
MATERIALS AND METHODS 
Subjects: 
A total of 12 male professional soccer players from the “Rayo 
Majadahonda” Team, in Spain, aged 18 to 22 years old, were 
randomly assigned to either experimental or control group. 
Athletes were in general good health and free of any health 
problems, including neurological, or systemic disorder that would 
JOURNAL OF ADVANCEMENT IN  
                                                     MEDICAL AND LIFE SCIENCES 
                                                                                                        
                                                                                                            Journal homepage: http://scienceq.org/Journals/JALS.php    
Research Article Open Access 
 
 J. of Advancement in Medical and Life Sciences                  Volume2/Issue 3                                                     ISSN: 2348-294X 2 
interfere with the results. All participants presented the same type 
of injury, consisting of ankle sprain Grade II with partial tearing of 
the ligaments, moderate pain, joint instability and swelling with 
bruising throughout the ankle and foot.  None of the participant 
showed any fracture. Athletes with bilateral ankle sprain, 
ipsilateral knee injury, third degree sprain, and previous ankle 
sprain within 6 months were excluded from the study.  
The participants were pair-matched, considering age (20.0±1.4 vs 
19.8±1.2), height (177.8±2.1 vs 178.3±3.1 cm), body weight 
(78.3±4.1 vs 79.2±3.2 kg), and extent of injury in control and 
experimental groups, respectively.  
The Evaluations for each subject included global assessment, 
medical exam, soft tissue sonogram, and the Karlsson and 
Peterson Scoring System for Ankle Function (KAFS) for both 
groups at beginning of the study and each subsequent week for a 
total of 4 weeks.  The KAFS is a validated disease-specific scale 
(0-100) that was developed to evaluate individuals with ankle 
injury. This scale measures eight parameters: instability, pain, 
swelling, stiffness, specific motion activities and need for support. 
Results are classified in four categories: excellent (90–100 
points), good (80–89 points), fair (60–79 points) or poor (≤60 
points). Patients were evaluated by team's doctors with soft tissue 
sonogram at days 1, 7, 14 and 21.  
Consumable: 
Both groups received conventional treatment for the ankle injury 
consisting of NSAI medication (as needed), application of a cold 
pack, complete or partial immobilization (with cast, brace, or 
bandage), partial weight bearing and crutches (as tolerated), 
instructions on early ankle exercise, home exercises, and 
resumption of sports and daily activities. 
The experimental group received 12 capsules of SE2® and 3 
capsules of Stemflo® daily for 4 weeks. StemFlo® is a dietary 
supplement containing fibrinolytic enzymes and antioxidants 
aimed at optimizing blood circulation in the fine vasculature. Both 
SE2® and StemFlo® were provided by Stemtech International, 
Inc., Florida, USA.   
The study was evaluated and approved by the Ethical Committee 
of Clinica Quantum (Spain). The protocol met all requirements 
established by the Conference of Helsinki for research on humans.  
 
RESULTS 
All 12 subjects completed the study. 
The overall severity of acute ankle injuries was similar in both 
groups at the beginning of the trial. Subjects in the experimental 
group showed significant improvement in their physical 
examination and soft tissue sonogram after 12-14 days. KAFS 
Analysis evidenced a noticeable difference in the course of 
recovery between the two groups (Figure 1). 
The SE2® group experienced a significantly greater reduction in 
pain, range of motion and joint stability associated with their ankle 
injury compared with control group. The time to heal the acute 
ankle injury and go back to playing soccer was on average 17 days 
for the SE2® group compared to 21 days and over for the control 
group.  After two weeks, the overall KAFS Median scores was 89 
for the experimental group and 72 for the control group. The 
maximum difference was seen at Day 17 when the level of 
recovery based on the KAFS Median scores per group have 
classified the individuals in 2 different categories: good (80–89 
points) for experimental group and, fair (60–79 points) for the 
Control group. (Figure 2)  
 
 
Figure 1.  Karlsson and Peterson Scoring System for Ankle 
Function (KAFS) before and 14 days after conventional therapy 
alone (Control) and conventional therapy accompanied along with 
the consumption of SE2® and StemFlo®.  Incorporation of SE2® 
and StemFlo® to the treatment protocol significantly improved 
ankle pain and stability, activity and overall score 14 days after the 
injury.  
 
Figure 2.  KAFS Median scores for the Control and Experimental 
groups, measured weekly over a period of 4 weeks (mean ± SE).  
The Experimental group receiving conventional therapy and 
consuming SE2® and StemFlo® showed faster recovery and could 
return to play on average one week before the control group 
receiving only conventional therapy.  
The study was intended only as a complementary protocol to 
expedite the recovery in athletes with this type of injuries. 
However, additional benefits were also revealed in the 
experimental group with regards to pain level. Individuals in the 
experimental group requested less anti-inflammatory and pain 
medication. 
 
CONCLUSION 
The development of protocols that not only efficiently treat sport 
injuries but also expedite the recovery is the keystone of the 
practice of sport medicine. In this scope, this study further 
documents the therapeutic potential of Endogenous Stem Cell 
Mobilization (Drapeau et al., 2012) in tissue repair, and more 
specifically in sport injuries.  
This study documented that the use the stem cell mobilizer SE2® 
along with StemFlo®, a fibrinolytic product aimed at improving 
blood microcirculation, in conjunction with conventional 
treatment reduced the recovery time from acute ankle injuries in 
 J. of Advancement in Medical and Life Sciences                  Volume2/Issue 3                                                     ISSN: 2348-294X 3 
male football players. The time to revert the acute ankle injury was 
on average 17 days for the SE2® group, and over 21 days for the 
athletes in the control group. Complete recovery was on average 
reduced by one week with the use of SE2® and StemFlo®.   
StemEnhance®, a concentrate of the cyanophyta Aphanizomenon 
flos-aquae that was documented to trigger bone marrow stem cell 
mobilization (Jensen et al., 2007) has been shown to significantly 
accelerate muscle repair after injection of cardiotoxin in the 
tibialis muscle of irradiated mice transplanted with bone marrow 
stem cells expressing green fluorescent protein (GFP) (Drapeau et 
al., 2010). In this study, muscle repair took place through the 
migration of circulating bone marrow–derived stem cells into the 
injured muscle and their subsequent differentiation into muscle 
cells, as shown by the incorporation of GPF-positive muscle cells 
in the regenerating muscle. StemEnhance® was also reported to 
promote tissue repair and significant improvements in single 
patient outcomes associated with a wide variety of health 
conditions (Drapeau et al., 2012).   
Other studies have documented the healing potential of bone 
marrow stem cell mobilization (Velasquez, 2007).  For example, 
Bozlar et al. (2005) injected the stem cell mobilizer G-CSF 
(25μg/kg/day) or 0.9% saline in rats that had been subjected to 
fracture of the tibiae. Radiological, histological and 
biomechanical assessment performed 3 weeks later revealed a 
significantly greater recovery in the G-CSF treated animals.  
Likewise, in mice subjected to burn and incision of the skin, 
animals treated with G-CSF showed greater recovery (Eroglu et 
al., 2004).  
CD34+ stem cells collected from peripheral blood following 
mobilization by using G-CSF were locally injected along with 
atelocollagen in rats subjected to medial collateral ligament 
injury, and results were compared with a control group only 
treated with atelocollagen.  Animals subjected to G-CSF and then 
injected with CD34+ stem cells showed much greater recovery, 
using macroscopic, histological, and biomechanical assessments 
(Tei et al., 2008).  Greater tissue repair was at least in part due to 
enhanced neovascularization in the treated animals.   
Endogenous Stem Cell Mobilization and more specifically the use 
of the stem cell mobilizer SE2® therefore emerge as possible 
complementary protocols to support the effectiveness of 
conventional treatment for sport ankle injuries, thereby decreasing 
the recovery time and reducing the critical off match time for the 
professional soccer player. Further investigations should be done 
with a broader spectrum of sport injuries.    
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